Page 9 - அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா Today - Breaking & Trending Today

ESOU 2021: EAU Section of the ESUR Lecture: Translational Research Best Papers of 2020

ESOU 2021: EAU Section of the ESUR Lecture: Translational Research Best Papers of 2020
(UroToday.com) The European Association of Urology (EAU) section of the ESUR lecture was provided by Dr. Kerstin Junker who presented the best papers of translational research published in 2020. Dr. Junker notes that the intestinal microbiome has a role in checkpoint inhibition, in particularly the treatment of metastatic renal cell carcinoma. Secondly, circulation DNA in the blood plasma has emerged as a new diagnostic tool, particularly for muscle-invasive bladder cancer.
Indeed, for the systemic therapy of metastatic renal cell carcinoma, there is a growing spectrum of single, combination and sequence options for therapy, with a need for stratification based on prognosis and predictive biomarkers. Dr. Junker notes that there are several parameters, including: ....

United States , Nordrhein Westfalen , Zachary Klaassen , Kerstin Junker , Nature Communications , European Association Of Urology , Georgia Cancer Center , Augusta University Medical College Of Georgia , European Association , Bacteria Composition Drives Primary Resistance , Renal Cell Carcinoma , Des Saarlandes , Urologic Oncologist , Assistant Professor , Medical College , Oncological Urology , ஒன்றுபட்டது மாநிலங்களில் , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , சக்கரி க்லாஸ்சேங் , இயற்கை தகவல்தொடர்புகள் , ஐரோப்பிய சங்கம் ஆஃப் சிறுநீரகம் , ஜார்ஜியா புற்றுநோய் மையம் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , ஐரோப்பிய சங்கம் , சிறுநீரகம் செல் புற்றுநோய் , சிறுநீரக புற்றுநோயியல் நிபுணர் ,

ESOU 2021: Surgical and Perioperative Challenges of Large Renal Tumors

ESOU 2021: Surgical and Perioperative Challenges of Large Renal Tumors
(UroToday.com) At the European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 virtual meeting, Dr. Arnaud Mejean discussed surgical and perioperative challenges of large renal tumors, particularly those with vena cava and lymph node involvement. Dr. Mejean notes that statistics from the SEER database suggest that 19% of patients present with locoregional disease, making this an important area of management. Historical data from an international multicenter study shows that based on UCLA Integrated Staging System (UISS) stratification for localized renal cell carcinoma (RCC), the 5-year survival rates were 92%, 67%, and 44% for low-, intermediate-, and high-risk groups, respectively. ....

United States , France General , Zachary Klaassen , Arnaud Mejean , University Of California Los Angeles , European Association Of Urology , Georgia Cancer Center , Augusta University Medical College Of Georgia , European Association , Oncological Urology , Staging System , Urologic Oncologist , Assistant Professor , Medical College , California Los Angeles , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , சக்கரி க்லாஸ்சேங் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா லாஸ் ஏஞ்சல்ஸ் , ஐரோப்பிய சங்கம் ஆஃப் சிறுநீரகம் , ஜார்ஜியா புற்றுநோய் மையம் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , ஐரோப்பிய சங்கம் , அரங்கு அமைப்பு , சிறுநீரக புற்றுநோயியல் நிபுணர் , உதவியாளர் ப்ரொஃபெஸர் ,

ASCO GU 2020: Next-Generation Sequencing (NGS) of Tumor Tissue from >4000 Men with mCRPC: The PROfound Phase III Study Experience

SHARE
ASCO GU 2020: Next-Generation Sequencing (NGS) of Tumor Tissue from >4000 Men with mCRPC: The PROfound Phase III Study Experience
San Francisco, California (UroToday.com) Metastatic castration-resistant prostate cancer (mCRPC) is a molecularly heterogeneous disease, with between 20 and 25% of patients with mCRPC harboring deleterious alterations in DNA damage repair genes, including those with direct or indirect roles in homologous recombination repair (HRR). These gene alterations, of which
BRCA1,
BRCA2, and
ATM are the most well-characterized, can confer sensitivity to PARP inhibition. The PROfound study showed that olaparib provides a statistically significant improvement in radiographic progression-free survival versus physician’s choice of enzalutamide or abiraterone in mCRPC patients with alterations in genes with a direct or indirect role in the HRR pathway. ....

United States , Northwestern University , San Francisco , Foundationone Cdx , Zachary Klaassen , Maha Hussain , Foundation Medicine , Roberth Lurie Comprehensive Cancer Center , Georgia Cancer Center , Augusta University Medical College Of Georgia , Northwestern University Feinberg School Of Medicine , Prostate Cancer Session , Clinical Oncology Genitourinary Cancers Symposium , Deputy Director , Comprehensive Cancer Center , Northwestern University Feinberg School , Assistant Professor , Medical College , Cancers Symposium , ஒன்றுபட்டது மாநிலங்களில் , வடமேற்கு பல்கலைக்கழகம் , சான் பிரான்சிஸ்கோ , சக்கரி க்லாஸ்சேங் , மஹா ஹுசைன் , அடித்தளம் மருந்து , ஜார்ஜியா புற்றுநோய் மையம் ,

ANZUP Mini ASM 2020: ANZUP Trial Update - The ENZAMET Trial

ANZUP Mini ASM 2020: ANZUP Trial Update - The ENZAMET Trial
(UroToday.com) The 2020 Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting (ASM) featured a session on ANZUP trial updates, including an update of the critical Phase III ENZAMET trial provided by Drs. Ian Davis, Arun Azad, and Lisa Horvath.
Dr. Davis started by recapping the 2019 publication of ENZAMET.
1 This trial randomly assigned 1,125 metastatic hormone-sensitive prostate cancer (mHSPC) patients from March 31, 2014, to March 24, 2017: 562 in the non-steroidal anti-androgen and 563 in the enzalutamide arm. The trial schema is as follows:
The treatment groups were well balanced for all important baseline factors. In the non-steroidal anti-androgen arm, 44% of patients were planned for early docetaxel, compared to 45% in the enzalutamide arm; 53% of patients in the non-steroidal anti-androgen arm were high volume metastatic burden compared to ....

New Zealand , South Australia , New South Wales , United States , Zachary Klaassen , Ian Davis , Arun Azad , Martin Stockler , Lisa Horvath , Chris Obrien Lifehouse , European Society Of Medical Oncology Annual Congress , Monash University , Eastern Health , Peter Maccallum Cancer Center , Augusta University Medical College Of Georgia , Central Clinical School University Of Sydney , Head Of The Eastern Health Clinical School , Department Of Medical Oncology , Cancer Trials Group , Georgia Cancer Center , Translational Research Committee , New Zealand Urogenital , Mini Annual Scientific Meeting , Medical Oncology Annual Congress , Eastern Health Clinical School , Associate Professor ,

SUO 2020: The Role of Prostate-Specific Membrane Antigen (PSMA) Scanning in Prostate Cancer (Up)Staging

SUO 2020: The Role of Prostate-Specific Membrane Antigen (PSMA) Scanning in Prostate Cancer (Up)Staging
(UroToday.com) At the 2020 virtual Society of Urologic Oncology s (SUO) prostate cancer session, Dr. Declan Murphy discussed the role of prostate-specific membrane antigen (PSMA) scanning in prostate cancer staging. Dr. Declan Murphy states that PSMA PET/CT is an obvious challenger to conventional imaging.
Because there was a lot of retrospective data (particularly in Australia) with PSMA PET-CT, Dr. Murphy and colleagues set out to assess prospectively the use of PSMA PET-CT among patients with high-risk prostate cancer before curative-intent surgery or radiotherapy – the proPSMA study. ....

United States , Zachary Klaassen , Declan Murphy , Peter Maccallum Cancer Centre , Society Of Urologic Oncology Annual Meeting , Society Of Urologic Oncology , Augusta University Medical College Of Georgia , Outcomes Research , Georgia Cancer Center , Australian Prostate Cancer Research Centre , Urologic Oncology , Royal Melbourne Hospital , Australian Prostate Cancer Research , Assistant Professor , Medical College , Urologic Oncology Annual Meeting , ஒன்றுபட்டது மாநிலங்களில் , சக்கரி க்லாஸ்சேங் , டெக்லான் மர்பி , பீட்டர் மக்காலம் புற்றுநோய் மையம் , சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல் , சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , ஔட்கம்ஸ் ஆராய்ச்சி , ஜார்ஜியா புற்றுநோய் மையம் , ஆஸ்திரேலிய ப்ராஸ்டேட் புற்றுநோய் ஆராய்ச்சி மையம் ,